Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis

Eleftherios Mylonakis, George Chalevelakis, George Saroglou, Peter Danias, Athina D. Argyropoulou, Olga Paniara, Sotirios A. Raptis

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Objective: To evaluate and compare in vivo the protective efficacy of unilamellar liposomal amphotericin B (L-AmB) with that of deoxycholate amphotericin B (D-AmB) in experimental endocarditis. Material and Methods: In the rabbit model of experimental Aspergillus fumigatus endocarditis, two doses of each antifungal agent (1.5 mg/kg each) were administered intravenously at 4 hours and at 30 minutes before challenge with an inoculum of A. fumigatus. Three days later, the animals were sacrificed, and the aortic vegetations were analyzed. Results: All 19 animals that did not receive chemoprophylaxis acquired endocarditis. In contrast, endocarditis developed in 2 of 10 animals pretreated with D-AmB (P<0.01) and 3 of 8 animals pretreated with L-AmB (P<0.01). Both D-AmB and L-AmB prevented the development of endocarditis due to A. fumigatus and decreased the concentration of fungi in the aortic vegetations by more than 1 log10. Conclusion: In the rabbit experimental model of Aspergillus endocarditis, D- AmB and L-AmB were equally effective in reducing the incidence of the infection and the tissue burden of fungi.

Original languageEnglish (US)
Pages (from-to)1022-1027
Number of pages6
JournalMayo Clinic Proceedings
Volume72
Issue number11
DOIs
StatePublished - 1997

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis'. Together they form a unique fingerprint.

Cite this